Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Anticipated CAGR of the Oral Hypoglycemic Agents Market, and What Factors Will Drive It?
In recent times, the oral hypoglycemic agents market has been experiencing consistent growth. The market size, which is projected to be $57.04 billion in 2024, is expected to rise to $59.57 billion by 2025 with a compound annual growth rate (CAGR) of 4.4%. Factors such as the increasing incidence of type 2 diabetes, a growing elderly populace, heightened consciousness about diabetes management, improved healthcare access in developing markets, and a preference for oral therapies over injections have contributed to the growth during the historical period.
Expectations suggest a continuous expansion in the market size for oral hypoglycemic agents in the coming years, with a projection to acquire a value of $72.09 billion by 2029, growing at a CAGR of 4.9%. This expected growth within the forecast period is linked to multiple factors such as the increasing demand for combined therapy approaches, supportive governmental health policies, a rise in the use of telemedicine for managing diabetes, an upward trend in investments towards R&D for diabetes cure, and an intensified focus on personalized treatment for diabetes. Noteworthy trends within this forecast period would encompass the creation of new oral anti-diabetic treatments, the development of fixed-dose mixtures, technological innovation in drug formulation, an emphasis on minimising drug-related side effects, and the incorporation of digital health equipment for tracking glucose levels.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24347&type=smp
What Are the Core Market Drivers Propelling Growth in the Oral Hypoglycemic Agents Industry?
The oral hypoglycemic agents market is predicted to expand due to the increasing prevalence of type 2 diabetes. Type 2 diabetes is a chronic metabolic condition where the body fails to use insulin effectively, resulting in high blood sugar levels. Sedentary lifestyles are leading to a surge in type 2 diabetes cases, due to their contribution to a lack of physical activity, obesity, and insulin resistance. Oral hypoglycemic agents aid in the management of type 2 diabetes by reducing blood sugar levels through different methods like improving insulin sensitivity, boosting insulin secretion, or decreasing glucose absorption. For example, the International Diabetes Federation (IDF), a non-profit organization based in Belgium, reported in April 2025 that approximately 589 million adults aged 20–79 globally have diabetes, with projections showing this number could substantially increase to 853 million by 2050. Consequently, as the prevalence of type 2 diabetes rises, so does activity in the oral hypoglycemic agents market.
How Is the Oral Hypoglycemic Agents Market Segmented?
The oral hypoglycemic agents market covered in this report is segmented –
1) By Product Type: Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy
2) By Administration Route: Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations
3) By Patient Type: Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities
5) By End users: Hospitals, Clinics
Subsegments:
1) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
2) By Metformin: Immediate-Release Metformin, Extended-Release Metformin (XR), Combination Metformin
3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose
5) By Immunotherapy: Teplizumab, Alum-Formulated GAD (GAD-Alum), Diamyd, Anti-CD3 Monoclonal Antibodies
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=24347&type=smp
Which Regions Are Driving the Next Phase of the Oral Hypoglycemic Agents Market Growth?
North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral hypoglycemic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Oral Hypoglycemic Agents Industry?
Leading corporations in the oral hypoglycemic agents market are concentrating on innovating superior therapeutic solutions, like dipeptidyl peptidase-4 (DPP-4) inhibitors, to enhance glycemic control in individuals with Type 2 diabetes. These are medications for type 2 diabetes that augment levels of the incretin hormone, which promotes insulin production in the body, subsequently reducing blood sugar levels. In a case in point, in June 2022, approval was granted for Sitagliptin Phosphate tablets, an autonomously developed oral hypoglycemic drug by Gan & Lee Pharmaceuticals Co. Ltd., a pharmaceutical firm based in China. This drug is aimed at effectively controlling Type 2 diabetes, providing an efficient cure by blocking the DPP-4 enzyme which is crucial for regulating blood glucose levels. The introduction of this medication signifies Ganlee Pharmaceuticals’ debut in the generic drug market, presenting a financially viable substitute for managing type 2 diabetes.
View the full report here:
https://www.thebusinessresearchcompany.com/report/oral-hypoglycemic-agents-global-market-report
How Is the Oral Hypoglycemic Agents Market Defined and What Are Its Core Parameters?
Oral hypoglycemic agents (OHAs) are medications taken by mouth to help lower blood glucose (sugar) levels in individuals with type 2 diabetes mellitus. These drugs work through various mechanisms, such as increasing insulin secretion, improving insulin sensitivity, reducing glucose absorption from the gut, or decreasing glucose production by the liver. Oral hypoglycemic agents are typically prescribed when lifestyle modifications such as diet and exercise alone are insufficient to control blood sugar.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24347
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
